Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTK787 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PTK787 | DRUG | Visudyne® + PTK787, 500 mg/day |
| Placebo | DRUG | Visudyne® + Placebo |
Inclusion criteria * Male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration * Patients with subfoveal choroidal neovascularization secondary to AMD Exclusion criteria * Eye disease that may result in visual loss during the study * Uncontrolled high blood pressure, de...
PTK787 is an investigational small molecule being studied for Von Hippel-Lindau Disease, wet age-related macular degeneration, and tumors. It has been evaluated in clinical trials for these conditions, including retinal and CNS hemangioblastoma related to VHL disease.
PTK787 is being developed by Novartis AG (NVS). The company has sponsored clinical trials of the drug for conditions including Von Hippel-Lindau Disease and wet age-related macular degeneration.
PTK787 is an investigational drug that has completed clinical trials. It has been studied in Phase 1 and Phase 2 trials, but it is not approved by the FDA and remains in clinical development.
PTK787 has been studied in completed trials including NCT00052013 for Von Hippel-Lindau Disease, NCT00138632 for wet age-related macular degeneration, and NCT00171587 for advanced tumors. These trials are all completed.
PTK787 is also known as vatalanib. In clinical trials, it has been referred to as PTK787/ZK 222584 and vatalanib, including in studies of advanced cancer.